Drugs / Nephropathy Formula No. 1
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06796660 | Sep 2025 → Dec 2027 expected | chronic kidney disease | Liu Zhanghong | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nephropathy Formula No. 1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06796660 ↗ |
| Action | Inhibit | “downregulating IL-6 mRNA expression, reducing IL-6 secretion, and thereby inhibiting the activation of the STAT3 signaling pathway” NCT06796660 ↗ |
| Route | Oral | “Nephropathy Formula No. 1 is given orally.” NCT06796660 ↗ |
| Target | IL6 | “downregulating IL-6 mRNA expression, reducing IL-6 secretion” NCT06796660 ↗ |